ERBB2 and breast cancer: Anti-HER2 treatment for HER2-positive (HER2+) BC has changed the natural history of this disease and has dramatically improved clinical outcomes in all disease stages, representing one of the greatest achievements in clinical oncology and providing clear evidence of the effectiveness of molecularly targeted therapeutics [4].